Red light, close to the body: what Well Red is actually building

Red light therapy has become a spa word. Panels are sold for skin, recovery, and a general sense of doing something modern about health. The more serious version has a narrower name, photobiomodulation, and a narrower question: do specific red and near-infrared wavelengths, at a known dose, change anything in living tissue?

Well Red Pty Ltd is a Tasmanian company working on that question for home use. It was founded in 2018 by Dr Catherine Hamilton, a retired medical practitioner who researches and writes on photobiomodulation, and Ron Brown, an electronics engineer who designs the devices. The split matters. One founder comes from clinical reading. The other comes from making the hardware do what the protocol says. The company is explicit that the light is not a cure. Its own clinic notes put it plainly: it can help with a range of problems, and it is not a treatment that replaces care.

What the wavelengths are doing

Visible red around 670 nanometres, and near-infrared around 810 nanometres, are the two bands Well Red builds around. Ordinary room light does not reach far past the skin. These wavelengths go further, through soft tissue and, with enough power and the right placement, toward bone and brain. Hamilton’s account of the mechanism is cellular rather than mystical. Mitochondria, the parts of the cell that make usable energy, appear to respond to these wavelengths. From that, researchers have described several downstream effects: support for cell survival, signals involved in making new cells, new small blood vessels that carry more oxygen and glucose, and a dampening of the inflammatory chemicals that drive pain and tissue irritation.

Well Red separates a direct effect from an indirect one. Direct means the light is aimed at the tissue you care about. On the head, the proposed results are neuroprotection, neurogenesis, better local blood supply, and less inflammation. Indirect is newer and less settled. Light on the lower body may still matter for the brain, the argument goes, because immune cells in the blood can carry a signal, and because gut microbes, which produce or regulate a large share of the body’s serotonin, communicate with the brain along the vagus nerve. Hamilton has written that near-infrared light can reach the abdomen and that both red and near-infrared wavelengths have been studied for their effect on gut flora. That literature is early. It is a reason for a pad on the belly. It is not a reason to skip food, sleep, or a doctor.

The devices, in plain terms

The Duo Coronet is a helmet of about 150 grams, light enough to wear without a session becoming an ordeal. Eight spokes carry two rows of LEDs: 40 at 670nm and 48 at 810nm, 88 in total, pulsed at 40 hertz. Coverage is the design point. A small cluster of lights on the forehead is a different product from a helmet that surrounds the skull. The standard program is 12 minutes of deep red followed by 12 minutes of near-infrared, then the unit switches off. Twenty-four minutes is the dose, not an open-ended glow.

The CoroNase is a nasal piece that runs in time with the helmet. The idea is anatomical. A helmet lights the crown and sides. Light through the nose is aimed underneath, toward deeper structures including the basal ganglia. Well Red presents the pair as the fuller option for people who want light in more of the brain, not as a required second purchase for every user.

The TheraPad is the flexible panel, two wavelengths, used off the head. Well Red describes it for pain, for the abdomen in the microbiome protocol, and in work on retinal cells. The gut suggestion on their site is specific: drape it over the abdomen for about twenty minutes once a day, and alternate red and near-infrared from one day to the next. If you forget which wavelength you used, they say either is acceptable.

Where wellness ends and illness begins

The company recommends the 24-minute helmet session for people thinking about sleep, cognitive sharpness, depression, and anxiety, and it also discusses the same device for Parkinson’s disease and the dementias. Those are not equivalent claims. Sleep and afternoon fog sit inside ordinary wellness. Parkinson’s, Alzheimer’s, and clinical depression do not.

On the illness side, the honest status is that a trial is underway, not that a result has been declared. An Australian New Zealand Clinical Trials Registry study is using the Duo Coronet at home in people with Alzheimer’s disease and Parkinson’s disease: each participant has a helmet, twice a day, 24 minutes a session, for 12 months. Early published interest in photobiomodulation for neurodegenerative disease is why that trial exists. It is not a finding the trial has finished. Anyone with those diagnoses should treat a device page as a hypothesis and talk to their own clinician before they buy one.

On the wellness side, the case is easier to live with, and easier to oversell. A dull head by 3 p.m., sleep that will not settle, a joint that aches in the same place, a mood that tracks digestion: people already try magnesium, a walk, and a stricter bedtime for these. A timed light session can sit beside those habits. It cannot stand in for them. Twenty-four minutes that end on their own is, if nothing else, a bounded practice. It does not ask you to become a different person. It asks you to sit still while a known wavelength runs a known clock.

How to read a red-light product

Most panels in the wellness market are beauty tools. They are fine for skin. They are the wrong comparison for a transcranial helmet. The questions worth asking are dull on purpose. Which wavelengths. How many LEDs, and where they sit. Whether the session length is fixed. Whether the maker will say what the device is not. Well Red publishes the protocol next to the hardware, names the founders, and points at a registered trial. That is a higher standard than a before-and-after photograph. It still leaves the stronger medical claims unproven.

Used with that limit in view, the company belongs in a wellness piece as a worked example, not as a promise. Red at 670 nanometres. Near-infrared at 810. A helmet that stops at 24 minutes. A pad for the abdomen or a sore joint. A retired doctor and an engineer in Tasmania who would rather describe the cellular story than the glow. For low mood, memory loss, or a movement disorder, the public evidence is early, the trial is the right place to watch, and a clinician remains the first call.

Well Red is at wellred.com.au.